Effect of Vitamin E Therapy on Sexual Functions of Uremic Patients in Hemodialysis

1992 ◽  
Vol 15 (11) ◽  
pp. 648-652 ◽  
Author(s):  
M. Yeksan ◽  
M. Polat ◽  
S. Türk ◽  
H. Kazanci ◽  
G. Akhan ◽  
...  
Keyword(s):  
Vitamin E ◽  
Serum Vitamin ◽  
Free Testosterone ◽  
Hemodialysis Patients ◽  
Prolactin Secretion ◽  
The Other ◽  
Serum Prolactin ◽  
Oral Vitamin ◽  
Before And After ◽  
Uremic Patients

Twenty-four uremic patients on hemodialysis who had never been treated with vitamin E or related drugs and 12 control patients with normal renal function were studied. Hemodialysis patients were randomly divided into two groups; 12 were treated with oral vitamin E (300 mg/day) for eight weeks and 12 uremic patients and 12 controls were given placebo. Serum vitamin E, prolactin, FSH, LH, and free testosterone levels were measured in all patients before and after treatment. After the vitamin E treatment serum prolactin levels were significantly decreased (50.8 vs 15.4 ng/ml, p<0.01). Vitamin E levels were significantly increased (1.11 vs 1.22 mg/dl, p<0.05). Serum FSH, LH and free testosterone were not affected. In the other two groups there were no significant changes. These results show that vitamin E treatment lowers prolactin levels in uremic hemodialysis patients. This might be due to inhibition of central prolactin secretion. Vitamin E inhibits pituitary gland hypertrophy in vitamin E-deficient rats.

Effect of Recombinant Human Erythropoietin (R-Huepo) Therapy on Plasma Ft3, FT4, TSH, FSH, LH, free Testosterone and Prolactin Levels in Hemodialysis Patients

1992 ◽  
Vol 15 (10) ◽  
pp. 585-589 ◽  
Author(s):  
M. Yeksan ◽  
N. Tamer ◽  
M. Cirit ◽  
S. Türk ◽  
G. Akhan ◽  
...  
Keyword(s):  
Free Testosterone ◽  
Hemodialysis Patients ◽  
Thyroid Stimulating Hormone ◽  
Sexual Disorders ◽  
Serum Prolactin ◽  
Control Group ◽  
Dialysis Session ◽  
Free Triiodothyronine ◽  
Human Erythropoietin ◽  
Stimulating Hormone

The aim of this study was to evaluate the effect of r-HuEPO treatment on free triiodothyronine (FT3), free thyroxine (FT4), thyroid stimulating hormone (TSH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), free testosterone and prolactin levels in uremic hemodialysis patients. Twenty-four uremic hemodialysis patients were given r-HuEPO with a dose 60 U/kg as intravenous bolus injection at the end of each dialysis session. Once the hematocrit value of the patient had reached a range of 30-35%, the dose was adjusted so as to keep the hematocrit levels constant. Twenty uremic dialysis patients were taken as control group. The above-mentioned hormone levels of patients and control group were determined before and 4 months after r-HuEPO treatment. After the treatment, serum prolactin levels significantly decreased in both sexes (36.8 ± 7.8 vs 22.9 ± 6.3 ng/ml and 78.3 ±13.3 vs 37.4 ± 10.4 ng/ml male and female, respectively). FT3 and FT4 significantly increased (1.17 vs 1.67 pg/ml, p<0.05, and 0.64 vs 0.084 ng/dl, p<0.05, respectively). TSH levels increased but those changes were not significant. There was no change in the level of any hormone in the control group. Also, the sexual functions of eight male patients treated with r-HuEPO improved and menstruation started again in four female patients. We concluded that r-HuEPO treatment especially decreases prolactin level in uremic hemodialysis patients. It is conceivable that correction of elevated prolactin levels could improve sexual disorders in these patients.

Vitamin E Supplementation Increases LDL Resistance to ex vivo Oxidation in Hemodialysis Patients

2003 ◽  
Vol 73 (4) ◽  
pp. 290-296 ◽  
Author(s):  
Badiou ◽  
Cristol ◽  
Morena ◽  
Bosc ◽  
Carbonneau ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Vitamin E ◽  
High Performance ◽  
Ex Vivo ◽  
Density Lipoprotein ◽  
Thiobarbituric Acid ◽  
Hemodialysis Patients ◽  
Ldl Oxidation ◽  
Oral Vitamin ◽  
Vitamin E Supplementation

Background: Oxidative stress and alterations in lipid metabolism observed in hemodialysis patients potentiate the low-density lipoprotein (LDL) oxidability, recognized as a key event during early atherogenesis. Objective: To explore the effects of an oral vitamin E supplementation on oxidative stress markers and LDL oxidability in hemodialysis patients. Methods: Fourteen hemodialysis patients and six healthy volunteers were given oral vitamin E (500 mg/day) for six months. Oxidative stress was assessed using: plasma and lipoprotein vitamin E levels [high-performance liquid chromatography (HPLC) procedure]; thiobarbituric acid reactive substances (TBARS, Yaggi method); and copper-induced LDL oxidation. All parameters were evaluated before initiation of vitamin E supplementation, and at three and six months thereafter. Results: At baseline, a significantly higher TBARS concentration and a higher LDL oxidability were observed in hemodialysis patients when compared to controls. After six months of vitamin E supplementation, TBARS and LDL oxidability were normalized in hemodialysis patients. Conclusion: Our data confirm that hemodialysis patients are exposed to oxidative stress and increased susceptibility to ex vivo LDL oxidation. Since oral vitamin E supplementation prevents oxidative stress and significantly increases LDL resistance to ex vivo oxidation, supplementation by natural antioxidants such as vitamin E may be beneficial in hemodialysis patients.

scholarly journals Influence of Oral Vitamin E Therapy on Micro-Inflammation and Cardiovascular Disease Markers in Chronic Hemodialysis Patients

Renal Failure ◽  
2006 ◽  
Vol 28 (5) ◽  
pp. 395-399 ◽  
Author(s):  
Magdalena Hodkova ◽  
Sylvie Dusilova-Sulkova ◽  
Marta Kalousova ◽  
Jirina Soukupova ◽  
Tomas Zima ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Vitamin E ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Oral Vitamin ◽  
Disease Markers

The Effect of Hemodialysis and Dialyzer Biocompatibility on Erythrocyte Glutathione-Defense System in Chronic Hemodialysis Patients

2005 ◽  
Vol 28 (6) ◽  
pp. 576-582 ◽  
Author(s):  
M.S. Alhamdani ◽  
A.F. Al-Najjar ◽  
A.H. Al-Kassir
Keyword(s):  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Oxygen Species ◽  
Defense System ◽  
Glutathione S Transferase ◽  
Metabolizing Enzymes ◽  
Before And After ◽  
Uremic Patients ◽  
A Minor ◽  
Glucose 6 Phosphate Dehydrogenase

Background Uremic patients, especially those receiving regular hemodialysis (HD) treatment, are at high risk of oxidative damage by noxious free radicals and reactive oxygen species (ROS). The erythrocyte glutathione-defense system (GSH-DS) is one of the major enzymatic means of scavenging and detoxifying ROS. This study aimed to elucidate the effect of HD and dialyzer biocompatibility on erythrocyte GSH-DS in uremic patients on maintenance HD treatment. Methods Twenty-five healthy volunteers and 42 HD patients were enrolled in this study. Blood samples were drawn immediately before and after HD session, and erythrocyte glutathione (GSH) level as well as the activities of the enzymes glucose-6-phosphate dehydrogenase (G6PD), glutathione peroxidase (GSH-Px), glutathione reductase (GSSG-Rd), and glutathione S-transferase (GST) were measured. To evaluate the effect of dialyzer type on the studied parameters the patients were were subdivided into two groups: those who had dialysis with cuprophane (CU) membranes (n=23) and those who received dialysis with the aid of polysulfone (PS) membranes (n=19). Results The activities of G6PD and GSH-Px as well as GSH level were significantly decreased in HD patients as compared with controls. On the other hand, the activities of GSSG-Rd and GST were significantly elevated among HD patients in comparison with control values. A single HD session, regardless of the type of dialyzer, did not induce any significant effect on any of the measured parameters, although G6PD activity increased significantly after dialysis. CU membrane did not result in any change in GSH or its metabolizing enzymes, while PS dialyzers exerted a minor but significant restoration in GSH-DS. Conclusion The antioxidant pool, as represented by GSH-DS, is significantly affected by dialyzer type in HD patients being significantly corrected with polysulfone dialyzer.

Influence of Parenteral Iron Therapy and Oral Vitamin E Supplementation on Neutrophil Respiratory Burst in Chronic Hemodialysis Patients

Renal Failure ◽  
2005 ◽  
Vol 27 (2) ◽  
pp. 135-141 ◽  
Author(s):  
Magdalena Hodkova ◽  
Sylvie Dusilova-Sulkova ◽  
Anna Skalicka ◽  
Marta Kalousova ◽  
Tomas Zima ◽  
...  
Keyword(s):  
Vitamin E ◽  
Respiratory Burst ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Iron Therapy ◽  
Oral Vitamin ◽  
Parenteral Iron ◽  
Parenteral Iron Therapy ◽  
Neutrophil Respiratory Burst ◽  
Vitamin E Supplementation

scholarly journals Atorvastatin and carnitine combination versus atorvastatin alone impacts on the lipid profile of haemodialyzed patients: A randomised clinical trial

2018 ◽  
Vol 6 (4) ◽  
pp. 165-171
Author(s):  
Hamid Noshad ◽  
Davoud Mohammadi Nejhad ◽  
Parastou Hoseini ◽  
Majid Montazer ◽  
Behnaz Ghamari ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Lipid Profile ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Randomised Clinical Trial ◽  
Hemodialysis Patients ◽  
The Other ◽  
Medical Sciences ◽  
Before And After

Introduction: Dyslipidemia is one of the most common problems in hemodialysis patients and healthcare system. Some studies have suggested the use of carnitine in the treatment of dyslipidemia in hemodialysis patients. This study was carried out aiming to evaluate the effect of atorvastatin and carnitine combination versus atorvastatin alone on the lipid profile of hemodialyzed patients. Methods: In this clinical trial, 50 hemodialysis patients referred to the educational centres of Tabriz University of Medical Sciences, Tabriz, Iran, for haemodialysis were enrolled. Patients were randomly assigned into two groups. In the first group, patients were treated with carnitine (1000 mg three times daily) and atorvastatin (10-80 mg/day based on the baseline lipid profile of the patients) and in the second group, the patients were treated with atorvastatin alone for six months. The levels of triglyceride (TG), cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and haemoglobin before and after intervention were compared. The side effects of carnitine administration were also evaluated. Results: Results showed that TG, cholesterol, and LDL levels were significantly lower in the carnitine group compared to those in the other group at the end of study (P < 0.050). In addition, HDL and haemoglobin levels were significantly higher in the carnitine group in comparison to the other group (P < 0.050). No major side effects of carnitine were observed among the patients. Conclusion: The use of carnitine plus atorvastatin combination is an effective and safe method in the treatment of dyslipidemia in patients undergoing hemodialysis without imposing significant side effects.

PROLACTIN RESPONSE TO METFORMIN IN CABERGOLINE-RESISTANT PROLACTINOMAS: A PILOT STUDY

2021 ◽  
Author(s):  
Luiz Henrique Corrêa Portari ◽  
Silvia Regina Correa-Silva ◽  
Julio Abucham
Keyword(s):  
Inhibitory Effect ◽  
Prolactin Secretion ◽  
Serum Prolactin ◽  
High Dose ◽  
Metformin Treatment ◽  
Human Pituitary ◽  
Day Range ◽  
Before And After

Introduction: Cabergoline is the treatment of choice for prolactinomas. However, 10-20% of prolactinomas are resistant to cabergoline. Metformin, a biguanide widely used in the treatment of diabetes mellitus, has been shown to reduce prolactin secretion in various pituitary tumor cell lineages both in vitro and in vivo and in human pituitary adenomas in vitro. The aim of this study is to test the effects of metformin addition to cabergoline treatment on prolactin levels in patients with resistant prolactinomas. Subjects and Methods: This is a prospective study performed in an outpatient clinic in a reference center. Ten adult patients (26-61 y) with prolactinomas (7M), persistent hyperprolactinemia (38-386 ng/mL) under cabergoline treatment (2-7 mg/week) for at least six months (6-108 mo), features of metabolic syndrome and not taking metformin were included. Metformin (1.0-2.5 g v.o./d) was given according to patients´ tolerance. Cabergoline doses were kept unchanged. Serum prolactin levels were measured before and after short- (30-60 d) and long- term (120-180 d) metformin treatment. Results: Mean prolactin levels did not show any significant changes (148 ± 39 ng/ml vs 138 ± 42 ng/ml vs 133 ± 39 ng/ml, before, at 30-60 days, and at 120-180 days, respectively, P=0.196) after metformin (mean dose: 1.25 g/day; range: 1.0-2.0 g/day). No patient reached a normal prolactin level during metformin treatment. Two patients were considered partial responders for exhibiting prolactin decreases ≥50% at a single time point during metformin. Conclusion: Metformin addition to ongoing high dose cabergoline treatment in patients with cabergoline-resistant prolactinomas failed to show a consistent inhibitory effect in serum prolactin levels.

Serum Vitamin E Levels in the Very Low Birth Weight Infant During Oral Supplementation

PEDIATRICS ◽  
1986 ◽  
Vol 77 (5) ◽  
pp. 636-640
Author(s):  
Patricia R. Neal ◽  
Pat Erickson ◽  
John C. Baenziger ◽  
John Olson ◽  
James A. Lemons
Keyword(s):  
Vitamin E ◽  
Very Low Birth Weight ◽  
Medical Center ◽  
Serum Vitamin ◽  
Serum Levels ◽  
Indiana University ◽  
Fluorometric Method ◽  
Oral Vitamin ◽  
Oral Supplementation ◽  
A Prospective Study

A prospective study was initiated to monitor serum tocopherol levels in all infants admitted to Indiana University Medical Center with birth weights &lt;1,500 g. These infants routinely receive 100 mg/kg/d of oral vitamin E (Aquasol E tocopherol acetate) every six hours. Levels are determined weekly or semiweekly using a modification of the fluorometric method of Hanson and Warwick. Vitamin E dosage is adjusted regularly to achieve levels ≥3.5 mg/dL. During the 6 months of this study, a total of 76 patients had 567 serum measurements. Of these, 220 levels (38%) were ≥3.5 mg/dL, 71 (13%) were ≥5.5 mg/dL, and 15 (2.7%) were &gt;8 mg/dL. Serum tocopherol levels often (1) remained ≥3.5 mg/dL for several days after oral supplementation was discontinued or (2) again became ≥3.5 mg/dL on a reduced dosage of 25 to 50 mg/kg/d. These data indicate that infants weighing &lt;1,500 g at birth who are receiving oral vitamin E supplementation at 100 mg/kg/d will have varied serum levels with a significant percentage exceeding 3.5 mg/dL.

Sign in / Sign up

Export Citation Format

Share Document